Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
  • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

• the present invention relates to an NMR imaging iron-containing preparation in the form of an effervescent tablet, powder, and the like, and an NMR imaging method utilizing the same.
• NMR ultra magnetic 1c Res 0nance
• NMR imaging which precesses in the direction of the field and generates net alignment in the magnetic field, takes advantage of this principle.
• NMR imaging when a patient is placed in a static magnetic field and a short radio frequency pulse is emitted from the coil surrounding the patient, this The magnetic field of the nucleus causes the alignment and the differential motion in the phase due to the new magnetic field in the nuclear magnetic moment.
• the pulse is stopped, the moment is distributed based on the original magnetostatic field and the distribution of the alignment and the age: i.
• a nuclear magnetic resonance signal receivable by the signal coil is generated, and by measuring the NMR signal, a proton density map of the target tissue can be represented.
• the above NMR signal is characteristic of the spin-lattice relaxation time (T, that is, the return of the nuclear magnetic moment to the flat-mouth alignment in a static magnetic field).
• T 2 Time and spin-spin relaxation time (T 2 , the time characteristic of the return of the nuclear magnetic moment to the irregular precession phase distribution) It depends heavily on the parameters, and these measurements can be used to diagnose the patient's tissue condition.
• Inorganic paramagnetic salts and various complexing agents containing these paramagnetic metal ions and organic nitrogen, phosphorus oxygen, ion, etc. mainly ethylenediamine Acetic acid, diethylammonium pentaacetic acid, and other aminopolyboronic acids
• organic chelate complex formed from the force mainly ethylenediamine Acetic acid, diethylammonium pentaacetic acid, and other aminopolyboronic acids
• the main purpose of the present invention is to make it easy to prepare into a pharmaceutical form, and to be easily soluble and dispersible in water, and easily and rapidly in water. Dissolving and dispersing into iron to provide an iron replenishment preparation suitable for taking o
• Another aim of the present invention is to provide NMR imaging iron-containing preparations that have a good storage stability.
• Another object of the present invention is to provide an iron-containing preparation for NMR imaging as a contrast agent showing a clear and accurate imaging effect on abdominal organs. It is to provide an NMR imaging method utilizing this ⁇ Disclosure of the invention>
• the iron-containing compound is 0.1 to 10% by weight (% by weight, hereinafter the same) as iron, sodium carbonate and / or sodium carbonate.
• the iron-containing agent for NMR imaging which contains 8 to 0% by weight of sodium hydrogencarbonate and 10 to 70% by weight of a neutralizer as an essential component, is used. O provided
• the preparations of the present invention are mainly in the form of tablets, condyles, powders or capsules.
• the preparations of the present invention especially those in the form of powders or tablets, have good solubility and dispersibility, and only need to be put into water at the time of use.
• the iron-containing compound It is easy to take (oral administration) because it can be easily dissolved and dispersed in water.
• the gastrointestinal tract can be expanded and extended by the generation of carbonic acid gas in the body, the shape of the gastrointestinal tract and the state of the lumen are also important. It also has the advantage of making it easier to understand the relationship with peripheral organs.
• the signal intensity of the lumen of the digestive tube can be increased, the wall of the digestive tube can be drawn, and the adjacent descending can be obtained.
• the enhancement of the contrast with the abdominal real organs such as the internal organs has a remarkable effect on NMR imaging.
• safe and low toxic substances can be used for each component used in the drug product of the present invention.
• the above iron-containing compound, sodium and / or sodium hydrogencarbonate or sodium hydrogencarbonate should be added to enhance the storage stability of the drug product.
• the present invention provides an iron-containing preparation for NMR imaging, which contains urea, a neutralizing agent, and lithium carbonate as a storage stabilizer.
• iron-containing compound in the present invention examples include, for example, ferrous citrate ammonium, ferric citrate ammonium, and ferric citrate.
• ferrous citrate ammonium sodium ferrous citrate, sodium ferric citrate, ferrous citrate, ferric citrate, ferrous dalconate, Ferrous pyrophosphate, ferric pyrophosphate, ferric lactate, ferrous sulfate, salt Ferric oxide, iron trinitrate, iron fin mouth fernium, ferrous fumarate, threonine iron, ferrous orotinate, sugar-containing Iron oxide or ferric gluconate is preferably employed.
• These iron-containing compounds are highly soluble or dispersible in water.
• any of these iron-containing compounds can be used as an effective component of a therapeutic agent for iron deficiency anemia, an anemia agent, a hematopoietic iron agent, and the like. It has been used as such and has high security.
• trivalent iron salts are used because they are safer, have better imaging effects, are more delicious, and are easier to drink. The use of trivalent citrates is especially preferred.
• the iron-containing compound is usually used as a powder having a particle size of 200 m or less.
• the above-mentioned iron-containing compounds may be used alone or in combination of two or more.
• the amount of iron is 0.1 to 10% as iron, preferably 0.5 to 5%.
• the formulation of the present invention has an accurate and clear contrast effect.
• the amount to be combined is about 10 to 300 mg per 1 'agent, and preferably about 25 to 300 mg. It is 10 O mg.
• sodium carbonate and / or sodium hydrogen carbonate and the neutralizing agent are combined together as a foaming component to form a foaming component. It is.
• the neutralizing agent neutralizes the sodium carbonate and the sodium hydrogencarbonate by contact with water to generate gaseous carbonate.
• An acid compound to be added This type of foaming has the effect of inflating and expanding the digestion tube, which is not to be imaged. It is very useful to understand the morphology and luminal state of the tube from NMR images.
• the neutralizing agent include organic acids such as L-tartaric acid, citric acid, fumaric acid, lactic acid, lingic acid, and ascorbic acid. Preference is given to using L-tartaric acid and citric acid, in particular.
• the E content of the foaming component is such that when the solution is acidic, the pH is about 3 to 5.5, especially 3.5 to 4.6. It is preferable that the compounding amount is such that the compound exhibits a degree of acidity, so that the iron-containing compound is rapidly dissolved. More specifically, the amount of each component is described as follows: sodium carbonate and Z or sodium hydrogen carbonate 8 to 60% neutralizer 0 to 0 70%.
• the preparation of the present invention is used in the form of a powder or the like, 20 to 50% of the above-mentioned range of the sodium carbonate and Z or sodium hydrogencarbonate is used. At 60%, it is particularly good at contrasting effects, while at 8 to 45%, it is particularly good taste and drinkable.
• sodium carbonate is 9 to 50%, especially 22 to 26%
• sodium hydrogen carbonate is 8 to 50%, especially 20%. It can be said that the range of about 45% is not only the contrast effect, but also the taste and the ease of taking. ,
• the neutralizing agent is used preferably in the range of 20 to 50%, particularly preferably in the range of 30 to 40%, and especially for sodium bicarbonate. On the other hand, it is preferable to use equivalent equivalents or larger equivalents.
• the carbonic acid blended as a foaming component is used.
• it contains potassium carbonate as a preservative stabilizer.
• sodium carbonate and sodium hydrogen carbonate are brought into contact with water depending on the neutralizing agent, which is an organic acid.
• the tablet is neutralized and generates carbonic acid gas, which promotes the disintegration and dissolution of the tablet, so that foaming occurs when a small amount of water is present during storage. Therefore, it is necessary to keep the product as dry as possible.
• the foaming preparation is stored in a hermetically sealed container with a drying agent, the water and crystal water remaining during diarrhea In some cases, foaming may occur.
• the above-mentioned potassium carbonate is extremely effective in preventing such foaming during storage, and it does not require the use of a desiccant during storage. In this way, foaming during storage can be prevented.
• the total amount of calcium carbonate is 0.2 to 13%, preferably 0.3 to 3%, more preferably 0.4 to 1% per preparation. This is appropriate to increase the stability of the preparation and to make it easier to take without sacrificing taste.
• the formulation of the present invention contains the above-mentioned iron-containing compound and a foaming component as essential components, and further includes various commonly known additives such as excipients.
• Agents, binders, disintegrants, lubricants, thickeners, surface active agents, osmotic pressure regulators, electrolytes, sweeteners, fragrances, pigments, pH modifiers Etc. can be added as needed.
• examples of the excipient include starches such as wheat starch, potato starch, cone starch dextrin, sucrose, grape sugar, and fruit.
• Saccharides such as sugar, maltose, xylose and lactose; sugars such as sorbitol, mannitol, manoletitol, and xylitol Glycosyltransferases such as calls, coupling sugagers, and paratose E-saccharides, canoledium phosphate, calcium sulfate, etc. It is.
• binders there are pasteurizers, sugars, gelatin, arabia gum, dextrin, methyl senorelose, CMC— Na, Polyvinyl pyrrolidone, Polyvinyl alcohol, Hydroxylene, Phenoleneolose, Xanthan gam, Peking Tin, tragacanth gum, casein, alginic acid, etc. are removed.
• Lubricants include, for example, loisin, isoloisin, L-nocline, cigar ester, hardening oil, stearic acid, Magnesium stearate, tanolec, macarogo and others are produced.
• Disintegrators include, for example, Abycel, CMC, CMC-Ca, and the like.
• Examples of the surface active agent include polysorbate, lecithin, and the like.
• sweeteners include sugars, sugar alcohols, aspenolates, dipeptides such as alimentum, stevia, saccharin, and the like. can give . These can be used by appropriately selecting the appropriate amount in consideration of the relationship with the essential components, the properties of the preparation, the production method, and the like.
• the preparations of the present invention contain an appropriate amount of vitamins, especially cyanocobalamin and bisconolevinic acid (vitamin C). Can be added and mixed. As a result, damage to living organisms It will also be possible to capture fins. Distribution of the above-mentioned vitamins, although the proportion is not particularly limited, the amount of vitamin C is usually up to 30% in taste. It is suitably between about 5 and 25%.
• the preparations of the present invention may be in the form of tablets, solid preparations such as granules, powders, capsules and the like.
• each preparation form it is possible to adopt the same method as that usually used according to each preparation form.
• weigh and mix each component in a certain amount and follow the usual direct powder compression method, dry or wet granulation method, etc. It can be manufactured.
• each component is weighed and mixed, and then packaged.
• each component is weighed and mixed, granulated and dried, and then divided.
• the thus obtained preparation of the present invention is in the form of effervescent tablets, powders, etc., which is poured into water to dissolve or disperse. It is administered by mouth. You may also take water after taking it in its original form.
• the dose of the drug of the present invention is appropriately determined according to the organ or tissue of the living body to be imaged, and usually 1.5 to 6 g of the drug is added to water. You only need to dissolve it in a dose of 0 to 300 m £ and take it.
• For contrast contrast imaging of the spleen apply 1-2 tablets of tablets prepared to about 1.5 to 6 g per tablet in water 100 to 30 Dissolve at 0 m and take.
• the product of the present invention can be used for the gastrointestinal tract, the gastrointestinal tract to the intestine, that is, the gastrointestinal tract wall of the stomach, duodenum, small intestine, large intestine, etc. film It can be used for NMR diagnosis of intestinal membranes.
• the drug product of the present invention is suitable for the contrast contrast display between the gastrointestinal tract and the solid organ in the abdomen, and the T, value is determined by the application. Brief description of the drawing to shorten the time>
• Fig. 1 is an abdominal contrast photograph before administration of the preparation of Example 1
• Fig. 2 is an abdominal contrast photograph after administration of the preparation of Example 1
• Figs. 3 and 4 are from another subject.
• Abdominal contrast photograph after administration of the preparation of Example 1 FIG. 5 is an abdominal contrast photograph before administration of the preparation of Example 20
• FIG. 6 is an abdominal contrast photograph after administration of the preparation of Example 20
• FIG. 9 is an abdominal contrast photograph of another subject after administration of the preparation of Example 20.
• the preparation of the present invention can be easily taken orally, and can expand and extend the digestive tube by foaming due to the foaming component. This makes it easier to understand the morphology, the state of the lumen, and the relationship with the surrounding organs, and at the same time, enhances the signal intensity in the gastrointestinal tract. Yes. Therefore, improvement in the diagnostic accuracy of various diseases is expected.
• Each component is mixed in the S mixture shown below, and the mixture is tabletted by a direct powder compression method to give foamed tablets (4.3 g per tablet). Obtained .
• Foamed tablets having the composition shown in Table 1 below were produced in the same manner as in Example 1.
• Iron content in one tablet (mg) 5 0 7 5 1 0 0 5 0 2 5 2 5 5 5 0
• a predetermined amount of each component shown in Table 2 is mixed in a large amount, and, if necessary, a sweetener and a flavoring agent are respectively mixed in appropriate amounts, and the mixture is packaged. Foaming powders of the weight (1 packet of rag) shown in the table were produced.
• FIGS. 3 and 4 clearly show the distinction between the various organs adjacent to the gastrointestinal tract.
• Fig. 3 the boundaries between the spleen and other organs can be clearly seen, and the anatomical head that is difficult to detect is also clearly visible.
• the spleen, tail, body, liver, kidney, blood vessels, etc. could be clearly identified, and the stomach wall could be clearly identified.
• FIGS. 5 and 6 are abdominal contrast photographs of the subject before and after taking it.
• Fig. 5 shows a T-weighted image of the stomach when water was taken to inflate the digestive tube.
• the water signal was weak, gray or black.
• the distinction between the lumen of the digestive lumen and the lumen of the digestive lumen is not clear.
• it is difficult to discriminate from the adjacent knee, liver, spleen, peritoneum, etc. as shown in the emphasized image in Fig. 6 after taking the drug.
• the signal intensity in the stomach is enhanced, rendered white, and the contrast with the surroundings is prominent.
• the stomach wall and the duodenal wall are clearly visible, and accordingly, the knee head and the knee body are clearly distinguished from peripheral organs and gastrointestinal tracts. It has been done.
• FIG. 7 is a T, weighted image after taking one packet of the foaming agent obtained in Example 20 with 300 m of water.
• the duodenum is similar to the duodenum in terms of T and signal, so it is difficult to clearly see its appearance, but the effervescent powder of this example is taken.
• the head of the head can be clearly and clearly delineated by the enlargement of the duodenum and the increase in signal intensity due to the generation of carbon dioxide.
• the stomach is similarly expanded sufficiently by water and carbonic acid gas, making the boundary between the stomach and the body lower and strengthening the contrast. .
• FIG. 8 due to the generation of carbon dioxide, the duodenum is enlarged, and the duodenal wall and the inner wall are clearly distinguished. Also, the ninth The figure also shows that the duodenum is enlarged, as in Figure 8.
• An effervescent tablet having the composition shown below was produced in the same manner as in Example 1.
• the obtained effervescent tablet of Example 21 was prepared in the same manner as in Example 21 except that potassium carbonate was not added thereto. ) And placed in a constant temperature room at 37 ° C to examine the swelling of the package, discoloration of tablets, dissolution time and change in taste. We examined the changes over time. As a result, the effervescent tablet of Example 21 to which potassium carbonate was added showed a swelling of the wrapping agent, a discoloration of the tablet, and a dissolution time as compared with the comparative tablet. It can be seen that the change in taste and taste is remarkable and small, and therefore the storage stability is excellent.

Landscapes

• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Radiology & Medical Imaging (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26539856

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (19)

Citations (1)

Family Cites Families (12)

• 1989
  • 1989-09-27 JP JP1252895A patent/JPH0678247B2/ja not_active Expired - Lifetime
  • 1989-10-03 WO PCT/JP1989/001009 patent/WO1990003800A1/ja not_active Ceased
  • 1989-10-03 US US07/476,438 patent/US5174987A/en not_active Expired - Lifetime
  • 1989-10-03 CA CA002000112A patent/CA2000112C/en not_active Expired - Lifetime
  • 1989-10-03 GB GB9012660A patent/GB2232592B/en not_active Expired - Lifetime
  • 1989-10-03 EP EP89910937A patent/EP0401377B1/en not_active Expired - Lifetime
  • 1989-10-03 DE DE89910937T patent/DE68909221T2/de not_active Expired - Lifetime
  • 1989-10-03 CH CH1984/90A patent/CH677880A5/de not_active IP Right Cessation

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events